Michael J. Fox attends the Michael J. Fox Foundation for Parkinson's Research gala at Cipriani South Street on Saturday, Oct. 29, 2022, in New York. (Photo by Charles Sykes/Invision/AP)

Up­dat­ed: New da­ta from a mas­sive Parkin­son’s tri­al could lead to break­throughs in drug de­vel­op­ment

US sci­en­tists af­fil­i­at­ed with the Michael J. Fox Foun­da­tion — named af­ter the Back to the Fu­ture ac­tor di­ag­nosed with Parkin­son’s dis­ease in 1991 — say they can mea­sure a pro­tein that plays a role in Parkin­son’s dis­ease, in a de­vel­op­ment that foun­da­tion CEO Deb­bie Brooks called “a ma­jor break­through.”

The study mea­sured a ver­sion of al­pha-synu­cle­in in pa­tient’s cere­brospinal flu­id, which opens up the pro­tein as a bio­mark­er for fu­ture di­ag­nos­tics and drug de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA